Cagrilintide vs Retatrutide
Cagrilintide and Retatrutide are both stocked here and are often considered together. This page sets out what differs between them: their class, the sizes and price per milligram, the shape of the published evidence behind each, and where each stands under Canadian law. It does not rank them, because which is appropriate depends on what is being studied.
Side by side
| Cagrilintide | Retatrutide | |
|---|---|---|
| Class | Long-acting amylin analogue (amylin receptor agonist) | GIP, GLP-1 and glucagon receptor agonist |
| Sizes and price | 5 mg · 10 mg — from $43.00 (best $8.55/mg) | 10 mg · 20 mg · 30 mg — from $87.00 (best $6.60/mg) |
| Published evidence | 8 cited studies; 8 controlled trials in people. | 6 cited studies; 6 controlled trials in people. |
| Models studied | human | human |
| Status in Canada | No Drug Identification Number | No Drug Identification Number; named in a Health Canada advisory |
| Formats | vial, starter | vial, pen, starter, kit, value |
Key differences
Cagrilintide 8 cited studies; 8 controlled trials in people. Retatrutide 6 cited studies; 6 controlled trials in people.
No published study has compared Cagrilintide and Retatrutide directly. Everything above is drawn from separate studies of each compound, so the two columns are not results from one experiment.
Both are supplied for in-vitro laboratory research only and neither is for human or veterinary use.
FAQ
What is the difference between Cagrilintide and Retatrutide?
Cagrilintide is long-acting amylin analogue (amylin receptor agonist); Retatrutide is gip, glp-1 and glucagon receptor agonist. The table above sets out the sizes, the price per milligram, the evidence behind each and their Canadian status.
Which has more published research, Cagrilintide or Retatrutide?
Cagrilintide has 8 cited studies on its page and Retatrutide has 6. Study count is not quality: the model each one used matters more, and both pages list that for every paper.
Are Cagrilintide and Retatrutide authorized in Canada?
No Drug Identification Number for Cagrilintide. No Drug Identification Number; named in a Health Canada advisory for Retatrutide. Health Canada authorizes a drug by issuing an eight-digit Drug Identification Number, and most research peptides have none.
Can Cagrilintide and Retatrutide be used together?
No published study has tested them in combination, so there is no evidence about what a pairing does. We supply both for laboratory research and make no claim about using them together.